Online inquiry

IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ5499MR)

This product GTTS-WQ5499MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets IL6 gene. The antibody can be applied in Crohn's disease (CD) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_000600.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3569
UniProt ID P05231
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-IL6, CDP 6038(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ5499MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ12894MR IVTScrip™ mRNA-Anti-TNF, OPRX-106(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA OPRX-106
GTTS-WQ9782MR IVTScrip™ mRNA-Anti-PCSK9, JS002(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA JS002
GTTS-WQ7445MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA GBR500
GTTS-WQ7069MR IVTScrip™ mRNA-Anti-FAP, FAP-IL2v(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA FAP-IL2v
GTTS-WQ2046MR IVTScrip™ mRNA-Anti-CD274, AHLX-20(Cap 1, 2-Thio-UTP, 30 nt-poly(A)) mRNA AHLX-20
GTTS-WQ7982MR IVTScrip™ mRNA-Anti-GHR, GX-H9(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA GX-H9
GTTS-WQ12251MR IVTScrip™ mRNA-Anti-IL6R, MRA(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MRA
GTTS-WQ6743MR IVTScrip™ mRNA-Anti-EGFR, DS 992(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA DS 992
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW